1.Influencing factors of the adverse outcome of pulmonary tuberculosis among adolescents in Hangzhou City between 2005 and 2020: a school-based retrospective cohort study.
Gang ZHAO ; Qing Lin CHENG ; Li XIE ; Zi Jian FANG ; Xu SONG
Chinese Journal of Preventive Medicine 2023;57(3):348-355
		                        		
		                        			
		                        			Objective: To explore the influencing factors of the adverse outcome of pulmonary tuberculosis (PTB) among adolescents in Hangzhou City between 2005 and 2020. Methods: A retrospective cohort study was used to collect the information of adolescent PTB patients with the onset of PTB occurring from January 1, 2005 to December 31 in 12 designated tuberculosis hospitals in Hangzhou, mainly including demographic, epidemiological, clinical manifestations, bacteriological characteristics and other data, through the China Management Information System for Infectious Disease Surveillance and Reporting and the follow-up survey. All patients were followed up and the end time was December 31, 2021. Multivariate Cox regression model was used to analyze the factors affecting the adverse outcome of these patients. Results: The mean age of 4 921 adolescent PTB patients was (18.9±3.6) years old, and the number of male and female patients were 3 074 and 1 847 respectively. The adverse outcome accounted for 14.7% (725) of all patients. Multivariate Cox regression model showed that eight risk factors, including management model from patients themselves or family members (HR=5.87, 95%CI: 4.55-7.64), molecular biology examination positive for PTB (HR=4.62, 95%CI: 2.98-7.19), the number of sputum smears-positive≥1 (HR=3.72, 95%CI: 2.87-4.83), non-standardized therapy regimens of PTB (HR=3.69, 95%CI: 2.95-4.64), history of retreated PTB (HR=2.22, 95%CI: 1.46-3.36), migrant adolescents (HR=1.89, 95%CI: 1.54-2.34), the number of chest X-ray scan (HR=1.83, 95%CI: 1.65-2.04), and severe PTB (HR=1.38, 95%CI: 1.02-2.05), were associated with the adverse outcome of adolescent PTB patients. Age (HR=0.94, 95%CI: 0.92-0.96), as the only protective factor, was associated with the adverse outcome of these patients. Conclusion: The management mode, molecular biological examination, chemotherapy program, history of tuberculosis, sputum smear examination, severity of tuberculosis, household residence, chest X-ray examination and age are associated with the adverse outcomes of adolescent PTB patients in Hangzhou.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Young Adult
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Tuberculosis, Pulmonary/drug therapy*
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Proportional Hazards Models
		                        			;
		                        		
		                        			Sputum
		                        			;
		                        		
		                        			Mycobacterium tuberculosis
		                        			
		                        		
		                        	
2.Analysis of changes in reporting and diagnosis of pulmonary tuberculosis among children in Liangshan Yi Autonomous Prefecture, Sichuan Province from 2019 to 2021.
Xiao Ran YU ; Shi Jin WANG ; Xue Mei YANG ; Min FANG ; Xi ZENG ; Hui QI ; Wei Wei JIAO ; Lin SUN
Chinese Journal of Preventive Medicine 2023;57(8):1153-1159
		                        		
		                        			
		                        			Objective: To compare the characteristics of children's pulmonary tuberculosis (PTB) cases reported from 2019 to 2021 before and during the implementation of the Action Plan to Stop Tuberculosis. Methods: Based on the reported incidence data and population data of child pulmonary tuberculosis (PTB) notified to the Chinese Center for Disease Control and Prevention (CDC) Tuberculosis Information Management System (TBIMS) from 2019 to 2021, the population information and clinically relevant information in different years were compared. Results: From 2019 to 2021, the reported cases of PTB in children were 363, 664 and 655, respectively. The number of reported cases increased significantly. The median age of the cases in children increased from 10.4 years in 2019 to 11.7 years in 2021 (P=0.005) over a three-year period. The etiological positive rate increased significantly from 11.6% (42/363) in 2019 to 32.2% (211/655) in 2021 (P<0.001). The positive rate of molecular testing increased most significantly, which became the main means of etiological detection and accounted for 16.7% (7/42), 62.0% (57/92) and 75.4% (159/211) of the children with positive etiological results, respectively. The resistance rates of isoniazid and rifampicin were analyzed in children with PTB who underwent drug sensitivity tests. The results showed that the resistance rates of isoniazid and/or rifampicin were 2/9, 3.9% (2/51) and 6.7% (11/163), respectively, with an average of 6.7% (15/223) over three years. The median patients' delay was 27 (12, 49) days in 2019. It was reduced to 19 (10, 37) days in 2020 and 15 (7, 34) days in 2021, both significantly lower than 2019 (P=0.009 and 0.000 2, respectively). Conclusion: From 2019 to 2021, the reported numbers of children with PTB and children with positive etiological results increase significantly in Liangshan Prefecture, while the diagnosis delay of patients significantly reduces.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Rifampin/therapeutic use*
		                        			;
		                        		
		                        			Isoniazid/therapeutic use*
		                        			;
		                        		
		                        			Tuberculosis, Pulmonary/drug therapy*
		                        			;
		                        		
		                        			Tuberculosis
		                        			;
		                        		
		                        			China/epidemiology*
		                        			
		                        		
		                        	
3.Analysis of changes in reporting and diagnosis of pulmonary tuberculosis among children in Liangshan Yi Autonomous Prefecture, Sichuan Province from 2019 to 2021.
Xiao Ran YU ; Shi Jin WANG ; Xue Mei YANG ; Min FANG ; Xi ZENG ; Hui QI ; Wei Wei JIAO ; Lin SUN
Chinese Journal of Preventive Medicine 2023;57(8):1153-1159
		                        		
		                        			
		                        			Objective: To compare the characteristics of children's pulmonary tuberculosis (PTB) cases reported from 2019 to 2021 before and during the implementation of the Action Plan to Stop Tuberculosis. Methods: Based on the reported incidence data and population data of child pulmonary tuberculosis (PTB) notified to the Chinese Center for Disease Control and Prevention (CDC) Tuberculosis Information Management System (TBIMS) from 2019 to 2021, the population information and clinically relevant information in different years were compared. Results: From 2019 to 2021, the reported cases of PTB in children were 363, 664 and 655, respectively. The number of reported cases increased significantly. The median age of the cases in children increased from 10.4 years in 2019 to 11.7 years in 2021 (P=0.005) over a three-year period. The etiological positive rate increased significantly from 11.6% (42/363) in 2019 to 32.2% (211/655) in 2021 (P<0.001). The positive rate of molecular testing increased most significantly, which became the main means of etiological detection and accounted for 16.7% (7/42), 62.0% (57/92) and 75.4% (159/211) of the children with positive etiological results, respectively. The resistance rates of isoniazid and rifampicin were analyzed in children with PTB who underwent drug sensitivity tests. The results showed that the resistance rates of isoniazid and/or rifampicin were 2/9, 3.9% (2/51) and 6.7% (11/163), respectively, with an average of 6.7% (15/223) over three years. The median patients' delay was 27 (12, 49) days in 2019. It was reduced to 19 (10, 37) days in 2020 and 15 (7, 34) days in 2021, both significantly lower than 2019 (P=0.009 and 0.000 2, respectively). Conclusion: From 2019 to 2021, the reported numbers of children with PTB and children with positive etiological results increase significantly in Liangshan Prefecture, while the diagnosis delay of patients significantly reduces.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Rifampin/therapeutic use*
		                        			;
		                        		
		                        			Isoniazid/therapeutic use*
		                        			;
		                        		
		                        			Tuberculosis, Pulmonary/drug therapy*
		                        			;
		                        		
		                        			Tuberculosis
		                        			;
		                        		
		                        			China/epidemiology*
		                        			
		                        		
		                        	
4.Analysis on medical care seeking of local and non-local pulmonary tuberculosis patients reported in Beijing, 2016-2021.
Shan Hua SUN ; Yan Yuan LI ; Yan XU ; Xian Yu WEI ; Ya Nan ZHANG ; Xi CHEN ; Xiaoxin HE
Chinese Journal of Epidemiology 2022;43(11):1746-1752
		                        		
		                        			
		                        			Objective: To analyze the medical care seeking of local and non-local pulmonary tuberculosis (TB) patients in Beijing from 2016 to 2021 and provide evidence for TB prevention and control in Beijing. Methods: The reported pulmonary TB data from 2016 to 2021 were collected from tuberculosis management information system and standard code management system of Chinese information system for disease control and prevention. The map data were obtained from the Institute of Geographic Sciences and Natural Resources Research. Excel 2016, SPSS 19.0, Python 3.9 and ArcGIS 10.6 softwares were used for data analysis and visualization for the inter-provincial mobility and inter-district mobility of pulmonary TB patient's medical care seeking in Beijing. Results: Among the reported pulmonary TB patients in Beijing from 2016 to 2021, 35.27%(24 307/68 926) were from 30 provinces (autonomous regions, municipalities) and Xinjiang Production and Construction Corps. The top 5 provinces with pulmonary TB patients medical care seeking in Beijing were Hebei (39.58%,9 620/24 307), Shanxi (8.82%,2 145/24 307), Inner Mongolia Autonomous Region (8.66%,2 105/24 307), Heilongjiang (6.95%,1 690/24 307) and Henan (6.88%,1 672/24 307). Patients from these 5 provinces accounted for 70.89% (17 232/24 307) of total pulmonary TB patients from other provinces. The pulmonary TB patients from other provinces mainly flowed to Tongzhou district of Beijing, accounting for 46.72% (11 356/24 307). These pulmonary TB patients mainly visited grade Ⅲ (A) hospitals, such as Beijing Chest Hospital of Capital Medical University with the highest proportion of 44.76% (10 880/24 307). Among pulmonary TB patients with current residence in Beijing, those sought medical care in other districts accounted for 55.06% (24 566/44 619). The outflow and inflow of TB cases' medical care seeking occurred in 16 districts of Beijing. The median proportion of cross district medical care seeking in 16 districts was 59.30% (56.05%, 65.13%). The inflow of the medical care seeking in Tongzhou, Haidian and Xicheng district was greater than the outflow, and the outflow was greater than the inflow in the other 13 districts. The pulmonary TB patients in Beijing mainly went to Beijing Chest Hospital in Tongzhou for medical care seeking, accounting for 42.18%(18 822/44 619). Conclusions: The proportions of non-local pulmonary TB patients seeking medical care in Beijing from 2016 to 2021 and local pulmonary TB patients seeking medical care in other districts in Beijing were high, and the hospitals where non-local pulmonary TB patients and local pulmonary TB patients sought medical care respectively belonged to grade Ⅲ (A) and municipal designated medical institutions of TB.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Tuberculosis, Pulmonary/therapy*
		                        			;
		                        		
		                        			Hospitals
		                        			;
		                        		
		                        			Asian People
		                        			;
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Chlorhexidine
		                        			
		                        		
		                        	
5.Complete reversal of severe pulmonary artery hypertension after antiretroviral treatment in a 43-year-old newly diagnosed HIV-infected male: A case report.
Christmae Maxine P. SOLON ; Jeremyjones F. ROBLES ; Gwendolyn PEPITO ; Chatie OLASIMAN
Philippine Journal of Internal Medicine 2022;60(1):49-53
Background: Human Immunodeficiency Virus (HIV) infection can be complicated by pulmonary arterial hypertension (PAH-HIV) wherein it can occur in approximately 0.5% of HIV patients. The benefit of ART in treating PAH-HIV is unclear in this population. Data on its safety, efficacy, and effect on the progression of PAH are conflicting and limited. In this case report, improvement in PAH was noted after ART was started.
Case: A 43-year-old, male, patient with no comorbidities, consulted due to a five-month history of progressive dyspnea, body malaise as well as weight loss. The patient is heterosexual with multiple sexual partners, an injection drug user, and was previously worked up for HIV, Hepatitis B, and C with unremarkable results. Initially managed as a case of Pneumonia but on CT scan was found to have a suprahilar mass which showed chronic granulomatous features. The positive GeneXpert confirms Pulmonary Tuberculosis (PTB). However, dyspnea was noted to progress thus 2D echocardiography was done which revealed severe pulmonary arterial hypertension with normal left ventricular function. Rescreening for HIV turned out positive thus started on anti-retroviral therapy (ART) with a noted improvement of symptoms as well as improvement and eventual normalization in pulmonary artery pressure. One year after initial diagnosis, undetectable viral load for HIV and Hepatitis C were noted along with improvement in CD4 count.
Conclusion: This is a rare case of severe pulmonary hypertension as an initial presentation for HIV infection. The approach to patients with incidental PAH may include work-up for HIV especially when risk factors are present. ART treatment may provide a favorable therapeutic option if initiated early.
Pulmonary Arterial Hypertension ; Human Immunodeficiency Virus ; Antiretroviral Therapy ; Pulmonary Tuberculosis ; Case Report
6.Identification of pulmonary paragonimiasis using Ziehl-Neelsen stain
Won Chul KIM ; Cho Rom HAHM ; Il Tae KIM ; Jin Hoi KOO ; Woo Jin JUNG
Allergy, Asthma & Respiratory Disease 2020;8(1):36-39
		                        		
		                        			
		                        			Pulmonary paragonimiasis and tuberculosis are endemic in Asia, South America, and Africa. However, differential diagnosis among the diseases is difficult because they present with similar clinical symptoms and diagnostic features. Here, we report a case of pulmonary paragonimiasis that was identified using Ziehl-Neelsen stain after initially being assessed for pulmonary tuberculosis. Following anti-Paragonimus chemotherapy, the patient's symptoms, laboratory test results, and lung lesions improved. Thus, the identification of Paragonimus westermani using Ziehl-Neelsen stain can be considered in the diagnosis.
		                        		
		                        		
		                        		
		                        			Africa
		                        			;
		                        		
		                        			Asia
		                        			;
		                        		
		                        			Diagnosis
		                        			;
		                        		
		                        			Diagnosis, Differential
		                        			;
		                        		
		                        			Drug Therapy
		                        			;
		                        		
		                        			Lung
		                        			;
		                        		
		                        			Paragonimiasis
		                        			;
		                        		
		                        			Paragonimus westermani
		                        			;
		                        		
		                        			South America
		                        			;
		                        		
		                        			Tuberculosis
		                        			;
		                        		
		                        			Tuberculosis, Pulmonary
		                        			
		                        		
		                        	
7.Accuracy of Xpert® MTB/RIF for the detection of tuberculosis and rifampicin-resistance tuberculosis in China: A systematic review and meta-analysis.
Jing Nan FENG ; Le GAO ; Yi Xin SUN ; Ji Chun YANG ; Si Wei DENG ; Feng SUN ; Si Yan ZHAN
Journal of Peking University(Health Sciences) 2020;53(2):320-326
		                        		
		                        			OBJECTIVE:
		                        			To systematically review the diagnostic accuracy of Xpert® Mycobacterium tuberculosis/rifampicin (Xpert® MTB/RIF) for the detection of active tuberculosis (TB) and rifampicin-resistance TB in Chinese patients.
		                        		
		                        			METHODS:
		                        			Four Chinese databases (SinoMed, CNKI, WanFang database, and VIP) and three English databases (PubMed, Embase, and The Cochrane Library) were searched from January 1, 2000 to September 15, 2017, to identify diagnostic tests about the accuracy of Xpert® MTB/RIF in Chinese patients. Two investigators screened the articles and extracted the information independently, and then the quality of each included study was evaluated by Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2. Bivariate random-effects meta-analysis was conducted to pool the sensitivity and specificity. In addition, subgroup analyses were performed based on patient type (TB patient and TB suspected patient), sample type (sputum, bronchoalveolar lavage fluid and others). All statistical analyses were conducted with Stata version 13.0.
		                        		
		                        			RESULTS:
		                        			A total of 47 articles were included in this systematic review. Most of them (38 articles) were in Chinese and only 9 articles were in English. All the articles were published during 2014 to 2017, and the sample size ranged from 31 to 3 151. Forty articles including 42 comparisons about TB were finally included with the pooled sensitivity of 0.94 (95%CI: 0.92, 0.95) and the pooled specificity of 0.87 (95%CI: 0.84, 0.91). Subgroup analysis showed that different patient and specimen types had no significant differences on sensitivity, but the specificity of sputum group was higher than that of bronchoalveolar lavage fluid. As for the detection of rifampicin-resistant TB, 33 articles (38 comparisons) were analyzed, the pooled sensitivity and specificity were 0.92 (95%CI: 0.89, 0.94) and 0.98 (95%CI: 0.97, 0.99) respectively. There were no significant differences between the patient and specimen in the subgroup analyses. The Deeks funnel plot showed a possible publication bias for detecting active tuberculosis (P=0.08) and no publication bias for rifampicin-resistant TB (P=0.24). The likelihood ratio scatter gram showed that in clinical applications, Xpert® MTB/RIF had a good diagnostic ability for detecting active tuberculosis, and it had good clinical diagnostic value in detecting rifampicin-resistant TB.
		                        		
		                        			CONCLUSION
		                        			Xpert® MTB/RIF has good sensitivity and specificity in detecting TB and rifampicin-resistant TB in Chinese people. In particular, it has good clinical value in diagnosing rifampicin-resistance TB.
		                        		
		                        		
		                        		
		                        			Antibiotics, Antitubercular/therapeutic use*
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			Diagnostic Tests, Routine
		                        			;
		                        		
		                        			Drug Resistance, Bacterial
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Rifampin/pharmacology*
		                        			;
		                        		
		                        			Sensitivity and Specificity
		                        			;
		                        		
		                        			Tuberculosis/drug therapy*
		                        			;
		                        		
		                        			Tuberculosis, Multidrug-Resistant/drug therapy*
		                        			;
		                        		
		                        			Tuberculosis, Pulmonary/drug therapy*
		                        			
		                        		
		                        	
8.Acceptance of Chemo-prophylaxis for Latent Tuberculosis Infection among High School/College Student Contacts of Tuberculosis Patients in Shanghai, China.
Yang LI ; Yi Hui ZHENG ; Li Ping LU ; Mei Xia YANG ; Chang Ming ZHOU ; Zheng An YUAN ; Yi HU ; Biao XU
Biomedical and Environmental Sciences 2018;31(4):317-321
		                        		
		                        			
		                        			Student contacts of tuberculosis (TB) cases are susceptible to latent tuberculosis infection (LTBI), and chemo-prophylaxis can reduce the risk of active TB among them. This study aimed to assess the acceptance of chemo-prophylaxis for LTBI among students, and their concerns regarding TB and its preventive treatment. A total of 560 students contacts were included in the investigation. The extent of contact was categorized from high to low (4 levels) with 12.9% of the students being close contacts. About 87.0% of the students were willing to receive chemo-prophylaxis if diagnosed with, LTBI, whereas 73 students declined. Students with a higher level of knowledge about TB (aOR = 1.11) or close contact with TB patients (aOR = 4.30) were more likely to accept treatment. To conclude, education regarding TB transmission is necessary. Moreover, LTBI detection should be integrated into the current school-based TB contact investigation.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Antitubercular Agents
		                        			;
		                        		
		                        			administration & dosage
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			epidemiology
		                        			;
		                        		
		                        			Contact Tracing
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Latent Tuberculosis
		                        			;
		                        		
		                        			drug therapy
		                        			;
		                        		
		                        			epidemiology
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Students
		                        			;
		                        		
		                        			Tuberculosis, Pulmonary
		                        			;
		                        		
		                        			drug therapy
		                        			;
		                        		
		                        			epidemiology
		                        			;
		                        		
		                        			prevention & control
		                        			;
		                        		
		                        			transmission
		                        			;
		                        		
		                        			Universities
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
9.Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report.
Xinxin XU ; Yinshi GUO ; Qiuying LI ; Ling YANG ; Jianqiang KANG
Frontiers of Medicine 2018;12(3):330-333
		                        		
		                        			
		                        			We observed a rare case of invasive mucinous adenocarcinoma (IMA) with a lepidic-predominant pattern accompanied by pulmonary tuberculosis. An 85-year-old man with repeated cough and sputum was admitted to Xinhua Hospital. T-SPOT test result was 212 pg/ml (reference value of negative is < 14 pg/ml), Mycobacterium tuberculosis culture was positive, and tuberculin skin test (PPD) was negative (skin induration < 5 mm). The patient was treated with several courses of antibiotics and anti-tuberculosis treatments. Repeated chest CT scans showed disease progression. Bronchoscopy yielded negative results. PET-CT scans showed negative results. A percutaneous lung biopsy revealed mucin-secreting cells lining the alveolar walls. IMA with a lepidic-predominant pattern was diagnosed after invasiveness was found after experimental treatments. Simultaneous occurrence of pulmonary tuberculosis and lung cancer are common; however, the present case of IMA having a lepidic-predominant pattern and coexisting with active tuberculosis has not been reported yet.
		                        		
		                        		
		                        		
		                        			Adenocarcinoma, Mucinous
		                        			;
		                        		
		                        			diagnosis
		                        			;
		                        		
		                        			pathology
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Antibiotics, Antitubercular
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			Disease Progression
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lung Neoplasms
		                        			;
		                        		
		                        			diagnosis
		                        			;
		                        		
		                        			pathology
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Mycobacterium tuberculosis
		                        			;
		                        		
		                        			isolation & purification
		                        			;
		                        		
		                        			Positron Emission Tomography Computed Tomography
		                        			;
		                        		
		                        			Pulmonary Alveoli
		                        			;
		                        		
		                        			pathology
		                        			;
		                        		
		                        			Tuberculosis, Pulmonary
		                        			;
		                        		
		                        			diagnosis
		                        			;
		                        		
		                        			drug therapy
		                        			
		                        		
		                        	
            

Result Analysis
Print
Save
E-mail